| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.3233/JAD-160623 |
| P698 | PubMed publication ID | 27662312 |
| P2093 | author name string | Renu Sharma | |
| Rashmi K Ambasta | |||
| Dhiraj Kumar | |||
| Niraj Kumar Jha | |||
| Pravir Kumar | |||
| Saurabh Kumar Jha | |||
| Abhishek Shrivastava | |||
| P2860 | cites work | Nicotinic receptors in neurodegeneration | Q36828916 |
| Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss | Q36877497 | ||
| Amyloid-β induces synaptic dysfunction through G protein-gated inwardly rectifying potassium channels in the fimbria-CA3 hippocampal synapse. | Q37043451 | ||
| NMDA receptor-dependent glutamate excitotoxicity in human embryonic stem cell-derived neurons | Q37050584 | ||
| Oxidative stress and mitochondrial dysfunction in neurodegeneration; cardiolipin a critical target? | Q37141481 | ||
| Mitochondrial reactive oxygen species regulate the strength of inhibitory GABA-mediated synaptic transmission | Q37159042 | ||
| Cholinergic system during the progression of Alzheimer's disease: therapeutic implications | Q37318152 | ||
| Plasticity of NMDA receptor NR2B subunit in memory and chronic pain | Q37385159 | ||
| Complement and microglia mediate early synapse loss in Alzheimer mouse models. | Q37391481 | ||
| Role of GABAA receptors in the physiology and pharmacology of sleep | Q37497506 | ||
| Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology | Q37620751 | ||
| Alzheimer's disease: synaptic dysfunction and Abeta | Q37636545 | ||
| Mitochondrial trafficking and anchoring in neurons: New insight and implications | Q37677601 | ||
| Microglial dysfunction in brain aging and Alzheimer's disease | Q37678533 | ||
| Tau protein modifications and interactions: their role in function and dysfunction | Q37684106 | ||
| Microglia and inflammation in Alzheimer's disease | Q37703295 | ||
| Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. | Q37734568 | ||
| An overview of curcumin in neurological disorders. | Q37788550 | ||
| Histamine neurons in the tuberomamillary nucleus: a whole center or distinct subpopulations? | Q21129323 | ||
| The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project | Q21261508 | ||
| The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn | Q24338247 | ||
| Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks | Q24622558 | ||
| Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model | Q24624879 | ||
| Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory | Q24645499 | ||
| Synapses and Alzheimer's disease | Q26269868 | ||
| Synaptic cell adhesion | Q26269885 | ||
| Amyloid-β-Induced Dysregulation of AMPA Receptor Trafficking | Q26748723 | ||
| Histamine and Immune Biomarkers in CNS Disorders | Q26748803 | ||
| P2Y Receptors in Synaptic Transmission and Plasticity: Therapeutic Potential in Cognitive Dysfunction. | Q26749031 | ||
| Reelin Proteolysis Affects Signaling Related to Normal Synapse Function and Neurodegeneration | Q26749956 | ||
| Emerging Link between Alzheimer's Disease and Homeostatic Synaptic Plasticity | Q26750576 | ||
| Comorbidity Factors and Brain Mechanisms Linking Chronic Stress and Systemic Illness | Q26765501 | ||
| Dysfunction of NMDA receptors in Alzheimer's disease | Q26766185 | ||
| Tau: The Center of a Signaling Nexus in Alzheimer's Disease | Q26768223 | ||
| Glia and TRPM2 Channels in Plasticity of Central Nervous System and Alzheimer's Diseases | Q26768288 | ||
| Implications of GABAergic Neurotransmission in Alzheimer's Disease | Q26768593 | ||
| Tau Oligomers: The Toxic Player at Synapses in Alzheimer's Disease | Q26773154 | ||
| "Is dopamine involved in Alzheimer's disease?" | Q26851680 | ||
| Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease | Q26853610 | ||
| The role of D-serine and glycine as co-agonists of NMDA receptors in motor neuron degeneration and amyotrophic lateral sclerosis (ALS) | Q27003135 | ||
| Neuropathological alterations in Alzheimer disease | Q27003314 | ||
| Role of redox signaling in neuroinflammation and neurodegenerative diseases | Q27012569 | ||
| Mitochondrial permeability transition pore is a potential drug target for neurodegeneration | Q27023850 | ||
| Aberrant insulin signaling in Alzheimer's disease: current knowledge | Q27024222 | ||
| Synaptic dysfunction and septin protein family members in neurodegenerative diseases | Q27026829 | ||
| GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin | Q27300708 | ||
| IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. | Q27315329 | ||
| Interactions between Aβ oligomers and presynaptic cholinergic signaling: age-dependent effects on attentional capacities | Q27331407 | ||
| Striatal-enriched protein tyrosine phosphatase in Alzheimer's disease. | Q27687325 | ||
| Mitochondrial Biology and Neurological Diseases | Q28076942 | ||
| The physiology, signaling, and pharmacology of dopamine receptors | Q28305030 | ||
| Molecular mechanisms of cognitive dysfunction following traumatic brain injury | Q28385324 | ||
| Nuclear translocation of jacob in hippocampal neurons after stimuli inducing long-term potentiation but not long-term depression | Q28477205 | ||
| Memantine Attenuates Alzheimer's Disease-Like Pathology and Cognitive Impairment | Q28551718 | ||
| Mitochondrial dynamics--fusion, fission, movement, and mitophagy--in neurodegenerative diseases | Q29615646 | ||
| APP processing and synaptic function | Q29615873 | ||
| TRP channels | Q29616673 | ||
| Tau-mediated neurodegeneration in Alzheimer's disease and related disorders | Q29618148 | ||
| Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice | Q30419141 | ||
| Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. | Q30446460 | ||
| Caspase-3 activation as a bifurcation point between plasticity and cell death. | Q30446892 | ||
| Impaired synaptic clustering of postsynaptic density proteins and altered signal transmission in hippocampal neurons, and disrupted learning behavior in PDZ1 and PDZ2 ligand binding-deficient PSD-95 knockin mice | Q30458150 | ||
| Mitochondrial dysfunction and calcium deregulation by the RanBP9-cofilin pathway | Q30557488 | ||
| Tau protein is essential for stress-induced brain pathology | Q30780692 | ||
| Nicotinic mechanisms influencing synaptic plasticity in the hippocampus | Q33830478 | ||
| The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? | Q33845251 | ||
| Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice | Q33938047 | ||
| The ubiquitin-proteasome pathway and synaptic plasticity | Q33994715 | ||
| Mitochondrial Complex I: structural and functional aspects | Q33997495 | ||
| Neuronal activity-regulated gene transcription in synapse development and cognitive function | Q34183712 | ||
| The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. | Q34289101 | ||
| 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease | Q34370099 | ||
| Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients | Q34393100 | ||
| Piracetam: a review of pharmacological properties and clinical uses. | Q34432813 | ||
| Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease | Q34544243 | ||
| Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. | Q45262354 | ||
| Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients. | Q45974067 | ||
| Activation of microglia by amyloid {beta} requires P2X7 receptor expression | Q46082033 | ||
| Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing | Q46240526 | ||
| Chronic stimulation of GABAA receptor with muscimol reduces amyloid beta protein (25-35)-induced neurotoxicity in cultured rat cortical cells | Q46493107 | ||
| A role for protein phosphatases 1, 2A, and 2B in cerebellar long-term potentiation. | Q46807880 | ||
| Methotrexate decreases PP2A methylation and increases tau phosphorylation in neuron | Q46975685 | ||
| Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection. | Q47917104 | ||
| Nicotine prevents synaptic impairment induced by amyloid-β oligomers through α7-nicotinic acetylcholine receptor activation. | Q48031081 | ||
| Dopaminergic neurotransmission dysfunction induced by amyloid-β transforms cortical long-term potentiation into long-term depression and produces memory impairment | Q48057460 | ||
| Beneficial effects of asiaticoside on cognitive deficits in senescence-accelerated mice | Q48094112 | ||
| Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor | Q48273018 | ||
| KCNQ5 K(+) channels control hippocampal synaptic inhibition and fast network oscillations | Q48345552 | ||
| Neuronal histamine deficit in Alzheimer's disease | Q48534393 | ||
| Lipopolysaccharide induces paired immunoglobulin-like receptor B (PirB) expression, synaptic alteration, and learning-memory deficit in rats | Q48626582 | ||
| Zinc Improves Cognitive and Neuronal Dysfunction During Aluminium-Induced Neurodegeneration | Q49029449 | ||
| Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. | Q50455488 | ||
| Cognitive impairment and increased Aβ levels induced by paraquat exposure are attenuated by enhanced removal of mitochondrial H(2)O(2). | Q51015803 | ||
| Noradrenergic mechanisms in neurodegenerative diseases: a theory | Q56864679 | ||
| β2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models | Q36760275 | ||
| Dynamic regulation of synaptic GABA release by the glutamate-glutamine cycle in hippocampal area CA1 | Q36774202 | ||
| Naringin Enhances CaMKII Activity and Improves Long-Term Memory in a Mouse Model of Alzheimer's Disease | Q36790422 | ||
| Seizure-Induced Regulations of Amyloid-β, STEP61, and STEP61 Substrates Involved in Hippocampal Synaptic Plasticity. | Q36809843 | ||
| Transient receptor potential channels in Alzheimer's disease. | Q36816373 | ||
| The role of G protein-coupled receptors in the pathology of Alzheimer's disease | Q37830311 | ||
| Recent advances in gene manipulation and nicotinic acetylcholine receptor biology. | Q37894276 | ||
| Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. | Q37961898 | ||
| Synaptic dysfunction in Alzheimer's disease. | Q37986675 | ||
| Neuronal calcium signaling and Alzheimer's disease | Q37997721 | ||
| Synaptic changes in Alzheimer's disease and its models | Q38017867 | ||
| Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. | Q38021399 | ||
| Neurotoxicity of amyloid β-protein: synaptic and network dysfunction | Q38023860 | ||
| Beta-amyloid monomer and insulin/IGF-1 signaling in Alzheimer's disease | Q38034089 | ||
| Serotonin: from top to bottom. | Q38055710 | ||
| Reelin signaling in development, maintenance, and plasticity of neural networks | Q38077005 | ||
| Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease | Q38106483 | ||
| The synaptic plasticity and memory hypothesis: encoding, storage and persistence | Q38168197 | ||
| Inhibitors of acetylcholinesterase and butyrylcholinesterase meet immunity. | Q38217301 | ||
| Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on. | Q38221488 | ||
| GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer's disease | Q38225536 | ||
| Mitogen-Activated Protein Kinase Phosphatase-2 Deletion Impairs Synaptic Plasticity and Hippocampal-Dependent Memory. | Q38605612 | ||
| Tau as the Converging Protein between Chronic Stress and Alzheimer's Disease Synaptic Pathology | Q38628679 | ||
| Substance P and Alzheimer's Disease: Emerging Novel Roles | Q38794975 | ||
| Synaptic pathology: A shared mechanism in neurological disease | Q38815857 | ||
| Neuroprotective Effect of Nanodiamond in Alzheimer's Disease Rat Model: a Pivotal Role for Modulating NF-κB and STAT3 Signaling. | Q39199984 | ||
| Nitric oxide signaling is recruited as a compensatory mechanism for sustaining synaptic plasticity in Alzheimer's disease mice | Q40027781 | ||
| Microglia function in Alzheimer's disease | Q41014561 | ||
| An integrated proteomics approach shows synaptic plasticity changes in an APP/PS1 Alzheimer's mouse model | Q41609863 | ||
| Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. | Q41757348 | ||
| Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation | Q42130064 | ||
| Soluble cell adhesion molecules in monocytes of Alzheimer's disease and mild cognitive impairment | Q42151500 | ||
| Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells | Q42437541 | ||
| Rotenone induces cell death of cholinergic neurons in an organotypic co-culture brain slice model | Q42454833 | ||
| Independent functions of hsp90 in neurotransmitter release and in the continuous synaptic cycling of AMPA receptors. | Q42461889 | ||
| Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation | Q42556634 | ||
| EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors | Q42723835 | ||
| 5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. | Q42771475 | ||
| Oxidative stress, progressive damage in the substantia nigra and plasma dopamine oxidation, in rats chronically exposed to ozone | Q43028591 | ||
| Dopamine protects neurons against glutamate-induced excitotoxicity | Q43159528 | ||
| Nitric oxide induces pathological synapse loss by a protein kinase G-, Rho kinase-dependent mechanism preceded by myosin light chain phosphorylation | Q43188182 | ||
| Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-induced sporadic dementia of Alzheimer's type | Q43775388 | ||
| Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders | Q44289376 | ||
| P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease | Q44292875 | ||
| Neuroprotection against Abeta and glutamate toxicity by melatonin: are GABA receptors involved? | Q44722653 | ||
| 1-Methyl-4-phenylpyridinium-induced apoptosis in cerebellar granule neurons is mediated by transferrin receptor iron-dependent depletion of tetrahydrobiopterin and neuronal nitric-oxide synthase-derived superoxide | Q44748873 | ||
| Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression | Q44915202 | ||
| RETRACTED: Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer's disease mouse model. | Q44968491 | ||
| α(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction | Q34661158 | ||
| Synaptic mitochondria in synaptic transmission and organization of vesicle pools in health and disease | Q34689753 | ||
| Reactive oxygen species in the regulation of synaptic plasticity and memory | Q34805998 | ||
| P2Y receptors in Alzheimer's disease | Q34860664 | ||
| Synaptic therapy in Alzheimer's disease: a CREB-centric approach | Q35064948 | ||
| The evolving biology of microglia in Alzheimer's disease. | Q35064995 | ||
| The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease | Q35195234 | ||
| Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis | Q35327172 | ||
| APOE4 enhances age-dependent decline in cognitive function by down-regulating an NMDA receptor pathway in EFAD-Tg mice. | Q35337169 | ||
| Okadaic acid: a tool to study regulatory mechanisms for neurodegeneration and regeneration in Alzheimer's disease | Q35403294 | ||
| Regulation of energy balance and body weight by the brain: a distributed system prone to disruption | Q35569563 | ||
| Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity | Q35579318 | ||
| Noradrenergic dysfunction in Alzheimer's disease. | Q35749478 | ||
| Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies | Q35752353 | ||
| Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells. | Q35816898 | ||
| BAG2 expression dictates a functional intracellular switch between the p38-dependent effects of nicotine on tau phosphorylation levels via the α7 nicotinic receptor | Q35819405 | ||
| Aging, synaptic dysfunction, and insulin-like growth factor (IGF)-1 | Q35947448 | ||
| Alteration in amyloid β42, phosphorylated tau protein, interleukin 6, and acetylcholine during diabetes-accelerated memory dysfunction in diabetic rats: correlation of amyloid β42 with changes in glucose metabolism | Q35949593 | ||
| Oridonin Attenuates Synaptic Loss and Cognitive Deficits in an Aβ1-42-Induced Mouse Model of Alzheimer's Disease | Q35956077 | ||
| Mechanism of oxidative stress in neurodegeneration | Q35996874 | ||
| Loss of functional GABA(A) receptors in the Alzheimer diseased brain | Q36056348 | ||
| Neuronal nicotinic acetylcholine receptors: neuroplastic changes underlying alcohol and nicotine addictions | Q36137598 | ||
| Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease | Q36187149 | ||
| Cytochrome c oxidase dysfunction in oxidative stress | Q36218389 | ||
| GABAergic inhibition of histaminergic neurons regulates active waking but not the sleep-wake switch or propofol-induced loss of consciousness | Q36302879 | ||
| Locus Coeruleus, norepinephrine and Aβ peptides in Alzheimer's disease | Q36310518 | ||
| Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice | Q36462902 | ||
| Pathological Tau Promotes Neuronal Damage by Impairing Ribosomal Function and Decreasing Protein Synthesis | Q36480214 | ||
| Elevated glucose and oligomeric β-amyloid disrupt synapses via a common pathway of aberrant protein S-nitrosylation | Q36511191 | ||
| Aβ-Induced Synaptic Alterations Require the E3 Ubiquitin Ligase Nedd4-1 | Q36534350 | ||
| The role of acetylcholine in learning and memory | Q36608229 | ||
| Always around, never the same: pathways of amyloid beta induced neurodegeneration throughout the pathogenic cascade of Alzheimer's disease | Q36611961 | ||
| The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases | Q36740187 | ||
| Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice | Q36759553 | ||
| P433 | issue | 4 | |
| P921 | main subject | neurotransmitter | Q162657 |
| Alzheimer's disease | Q11081 | ||
| P304 | page(s) | 1017-1039 | |
| P577 | publication date | 2016-09-23 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | Stress-Induced Synaptic Dysfunction and Neurotransmitter Release in Alzheimer's Disease: Can Neurotransmitters and Neuromodulators be Potential Therapeutic Targets? | |
| P478 | volume | 57 |
Search more.